Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEFINE: MRI-defined Focal Boosts with SBRT for Prostate Cancer
NCT05851547Phase 2Recruiting
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Nov 2023
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by Ottawa Hospital Research Institute. Primary endpoint: Genitourinary and gastrointestinal toxicity at 12 months. Started Nov 2023; status: recruiting.
Beyond the preview
Go deeper on NCT05851547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05851547.